Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul;29(4):268-274.
doi: 10.1097/CCO.0000000000000374.

Adult desmoid tumors: biology, management and ongoing trials

Nicolas Penel  1 , Frédéric Chibon, Sébastien Salas
Affiliations
Review

Adult desmoid tumors: biology, management and ongoing trials

Nicolas Penel et al. Curr Opin Oncol. 2017 Jul.

Abstract

Purpose of review: To summarize the current knowledge about the biology and clinical management of adult desmoid tumors.

Recent findings: In the past decade, we have learned that desmoid tumors are driven by alterations of the Wnt/APC/β-catenin pathway, sporadic desmoid tumors are associated with somatic mutations of CTNNB1, and germline mutations of APC and somatic mutations of CTNNB1 are probably mutually exclusive. One-third of desmoid tumors are misdiagnosed; a second pathological opinion is therefore of major importance for desmoid tumor. Surgery is no longer regarded as the cornerstone of desmoid tumors; several retrospective studies have demonstrated the safety of a 'wait and see' policy in sporadic abdominal wall desmoid tumor. Desmoid tumors is no longer regarded as an absolute contraindication for pregnancy. At least two new investigational drugs targeting the Wnt/APC/β-catenin pathway are currently being developed.

Summary: The management of desmoid tumors requires multidisciplinary expertise by an experienced team. We must fully understand the physiopathology of the disease (factors influencing the natural history of the disease) and learn how to avoid desmoid tumors occurrence in patients with APC germline mutations, identify reliable prognostic/predictive factors and better assess the efficacy of systemic treatment.

PubMed Disclaimer

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

References

    1. Wu C, Nik-Amini S, Nadesan P, et al. Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. Cancer Res 2010; 70:7690–7698. - PubMed
    1. Penel N, Coindre JM, Bonvalot S, et al. Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France. Eur J Cancer 2016; 58:90–96. - PubMed

    2. This nationwide 4-year survey demonstrates that one third of desmoid tumors are misdiagnosed outside reference center and stresses the importance of second opinion by expert pathologist. Moreover, the set-up of reference network was associated with dramatic decrease in delay between initial diagnosis and first consultation experienced physician in management of desmoid tumor (from 400 to 60 days).

    1. Cheon SS, Cheah AY, Turley S, et al. Beta-catenin stabilization dysregulates mesenchymal cell proliferation; motility, and invasiveness and causes aggressive fibromatosis and hyperplasic cutaneous 189 wounds. Proc Natl Acad Sci USA 2002; 99:6973–6978. - PMC - PubMed
    1. Li J, Wang CY. TBL1-TBLR1 and beta-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis. Nat Cell Biol 2008; 10:160–169. - PubMed
    1. Salas S, Chibon F, Noguchi T, et al. Molecular 194 characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer 2010; 49:560–568. - PubMed